Research HER
Related Resources for this page:
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- HER Signaling
- How are ADCs designed to work?
- Hypoxic tumor environment promotes angiogenesis
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Summary
- Targeting cancers with ADCs
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- What are ADCs?
- Antibody-Drug conjugates
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Summary
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- Traditional Monoclonal Antibodies
- Glossary
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Obinutuzumab (GA101)
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- Antibody-Drug Conjugates
Share
HER1 Epidermal Growth Factor Receptor (EGFR) Overview
— Herbst RS and Bunn PA Jr, Clin Cancer Res, 20031
These findings indicate that there is an important role for aberrant EGFR signaling in the development and progression of various human tumors. In addition, they provide a strong rationale for EGFR-TK as a target molecule for the development of new cancer therapies.
HER1, also known as the epidermal growth factor receptor (EGFR), drives the development of multiple solid tumor types. This section of ResearchHERPathways.com focuses on HER1/EGFR signaling, how HER1/EGFR is measured, its prognostic value, and its relationship with specific tumor types. Click on the links below to learn more.